Innovation News

New Brunswick, NJ – Johnson & Johnson announced that its Janssen Pharmaceutical Companies will invest$10 millionin a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease. The investment will be made through its affiliate venture arm, Johnson & Johnson Innovation.

"At Johnson & Johnson, we are proud to work with the UK government and other partners on the establishment of the global Dementia Discovery Fund," said Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals and Chief Scientific Officer, Johnson & Johnson. "Alzheimer's disease is one of the most critical public health problems, and it will be solved by working collaboratively. This means supporting leading scientists and working side by side with industry, government, and other groups to fund promising science that will lead to new treatments."Dementia is a progressive condition that slowly robs people of their ability to think and function. It is caused by a variety of brain illnesses that affect memory, thinking, behavior and the ability to perform everyday activities. Dementia can be overwhelming for people who have it and for their caregivers and families. A lack of awareness and understanding of dementia results in stigma, barriers to diagnosis and care, and negative physical, psychological, and economic effects.

Approximately 44 million people worldwide suffer from dementia. This number is expected to double by 2030 and more than triple by 2050.

Johnson & Johnson and its Janssen Pharmaceutical Companies have a strong tradition of investment in innovative science and collaborations in Alzheimer's disease. Janssen has a comprehensive Alzheimer's disease research and development program, focused on slowing or preventing disease progression. Janssen researchers are studying hallmarks of the illness – amyloid plaques, tau tangles and loss of nerve cell connections in the brain, all of which can lead to Alzheimer's dementia. Their research projects include small molecule treatments, antibodies and therapeutic vaccines. Janssen also has many current scientific collaborations in this area.